他汀类药物在卵巢癌中的研究进展

doi:10.12280/gjfckx.20220624

摘要/Abstract

摘要：

他汀类药物是3-羟基-3-甲基戊二酰辅酶A还原酶（3-hydroxy-3-methylglutaryl-coenzyme A reductase，HMGCR）抑制剂，可通过减少胆固醇生物合成和诱导低密度脂蛋白受体表达而降低血浆胆固醇水平，广泛应用于高脂血症的治疗和心脑血管疾病的预防；此外，他汀类药物可能通过阻断细胞周期进展、诱导细胞凋亡、抑制血管生成、抑制肿瘤生长和转移而具有潜在的抗癌作用。卵巢癌预后较差，给患者造成了严重的经济和心理负担。他汀类药物通过抑制甲羟戊酸（mevalonic acid，MVA）途径、促进铁死亡、调节细胞自噬和调节肿瘤微环境（tumor microenvironment，TME）等多种途径发挥抗肿瘤作用和改善卵巢癌化疗耐药现象，同时在某种程度上可抑制卵巢癌细胞增殖，降低卵巢癌患病风险，改善预后，协同并增强化疗药物抗肿瘤作用，降低复发率。综述他汀类药物在卵巢癌的预防和治疗中的研究新进展，以期对未来临床实践提供帮助。

关键词: 卵巢肿瘤, 羟甲基戊二酰基CoA还原酶抑制剂, 抗肿瘤药, 治疗, 预后

Abstract:

Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors that reduce plasma cholesterol level by reducing cholesterol biosynthesis and inducing changes in low-density lipoprotein receptor expression. It is widely used in the treatment of hyperlipidemia and the prevention of cardiovascular and cerebrovascular diseases. In addition, statins may have potential anticancer effects by blocking cell cycle progression, inducing apoptosis, inhibiting angiogenesis, and inhibiting tumor growth and metastasis. Ovarian cancer has a poor prognosis and causes severe economic and psychological burden to patients. Statins exert anti-tumor effects and improve the chemoresistance of ovarian cancer by inhibiting mevalonic acid (MVA) pathway, promoting ferroptosis regulating autophagy and tumor microenvironment (TME). Studies have shown that statins, to some extent, can inhibit ovarian cancer cell proliferation, reduce the risk of ovarian cancer, improve the prognosis, synergize and enhance the anti-tumor effects of chemotherapy drugs, and reduce the recurrence rate. This article reviews the research progress of statins in the prevention and treatment of ovarian cancer, in order to provide help for future clinical practice.

Key words: Ovarian neoplasms, Hydroxymethylglutaryl-CoA reductase inhibitors, Antineoplastic agents, Therapy, Prognosis

李玉兰, 肖晨朦, 刘晓, 韩逢皎, 岳玲, 许飞雪. 他汀类药物在卵巢癌中的研究进展[J]. 国际妇产科学杂志, 2023, 50(1): 25-29.

LI Yu-lan, XIAO Chen-meng, LIU Xiao, HAN Feng-jiao, YUE Ling, XU Fei-xue. Research Progress of Statins in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(1): 25-29.

参考文献 30

[1]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559. doi: 10.3322/caac.21559
[2]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[3]	Mohammadian-Hafshejani A, Sherwin C, Heidari-Soureshjani S. Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis[J]. J Prev Med Hyg, 2020, 61(3):E331-E339. doi: 10.15167/2421-4248/jpmh2020.61.3.1497. doi: 10.15167/2421-4248/jpmh2020.61.3.1497 pmid: 33150223
[4]	Yang J, Li C, Shen Y, et al. Impact of statin use on cancer-specific mortality and recurrence: A meta-analysis of 60 observational studies[J]. Medicine (Baltimore), 2020, 99(14):e19596. doi: 10.1097/MD.0000000000019596. doi: 10.1097/MD.0000000000019596
[5]	Akinwunmi B, Vitonis AF, Titus L, et al. Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study[J]. Int J Cancer, 2019, 144(5):991-1000. doi: 10.1002/ijc.31758. doi: 10.1002/ijc.31758 pmid: 30006925
[6]	Zhu PF, Wang MX, Chen ZL, et al. Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins[J]. Front Oncol, 2021, 11:761107. doi: 10.3389/fonc.2021.761107. doi: 10.3389/fonc.2021.761107
[7]	Göbel A, Zinna VM, Dell′Endice S, et al. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer[J]. BMC Cancer, 2020, 20(1):703. doi: 10.1186/s12885-020-07164-x. doi: 10.1186/s12885-020-07164-x pmid: 32727400
[8]	Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications[J]. Cell Res, 2021, 31(2):107-125. doi: 10.1038/s41422-020-00441-1. doi: 10.1038/s41422-020-00441-1 pmid: 33268902
[9]	Xu T, Ding W, Ji X, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy[J]. J Cell Mol Med, 2019, 23(8):4900-4912. doi: 10.1111/jcmm.14511. doi: 10.1111/jcmm.14511 pmid: 31232522
[10]	Li L, Qiu C, Hou M, et al. Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy[J]. Front Oncol, 2021, 11:665945. doi: 10.3389/fonc.2021.665945. doi: 10.3389/fonc.2021.665945
[11]	Li D, Zhang M, Chao H. Significance of glutathione peroxidase 4 and intracellular iron level in ovarian cancer cells-"utilization" of ferroptosis mechanism[J]. Inflamm Res, 2021, 70(10/11/12):1177-1189. doi: 10.1007/s00011-021-01495-6. doi: 10.1007/s00011-021-01495-6
[12]	Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication[J]. Free Radic Biol Med, 2019, 133:144-152. doi: 10.1016/j.freeradbiomed.2018.09.014. doi: 10.1016/j.freeradbiomed.2018.09.014
[13]	Nassour J, Radford R, Correia A, et al. Autophagic cell death restricts chromosomal instability during replicative crisis[J]. Nature, 2019, 565(7741):659-663. doi: 10.1038/s41586-019-0885-0. doi: 10.1038/s41586-019-0885-0
[14]	Hu Z, Cai M, Zhang Y, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway[J]. Cell Cycle, 2020, 19(2):193-206. doi: 10.1080/15384101.2019.1704537. doi: 10.1080/15384101.2019.1704537 pmid: 31885310
[15]	Kobayashi Y, Takeda T, Kunitomi H, et al. Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer[J]. Pharmaceuticals (Basel), 2022, 15(2):124. doi: 10.3390/ph15020124. doi: 10.3390/ph15020124
[16]	Jiang W, Hu JW, He XR, et al. Statins: a repurposed drug to fight cancer[J]. J Exp Clin Cancer Res, 2021, 40(1):241. doi: 10.1186/s13046-021-02041-2. doi: 10.1186/s13046-021-02041-2
[17]	Si X, Xu F, Xu F, et al. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway[J]. Biomed Pharmacother, 2020, 123:109717. doi: 10.1016/j.biopha.2019.109717. doi: 10.1016/j.biopha.2019.109717 pmid: 31865146
[18]	Zhang Q, Ding J, Wang Y, et al. Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review)[J]. Oncol Rep, 2022, 47(5):102. doi: 10.3892/or.2022.8313. doi: 10.3892/or.2022.8313
[19]	Jin H, He Y, Zhao P, et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery[J]. Theranostics, 2019, 9(1):265-278. doi: 10.7150/thno.27246. doi: 10.7150/thno.27246 pmid: 30662566
[20]	de Wolf E, Abdullah MI, Jones SM, et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer[J]. Sci Rep, 2017, 7(1):5410. doi: 10.1038/s41598-017-05595-4. doi: 10.1038/s41598-017-05595-4 pmid: 28710496
[21]	Ma X, Bi E, Lu Y, et al. Cholesterol Induces CD8(+) T Cell Exhaustion in the Tumor Microenvironment[J]. Cell Metab, 2019, 30(1):143-156.e5. doi: 10.1016/j.cmet.2019.04.002. doi: 10.1016/j.cmet.2019.04.002
[22]	Irvin S, Clarke MA, Trabert B, et al. Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer[J]. Cancer Causes Control, 2020, 31(10):869-879. doi: 10.1007/s10552-020-01327-8. doi: 10.1007/s10552-020-01327-8
[23]	Rao PS, Rao US. Statins decrease the expression of c-Myc protein in cancer cell lines[J]. Mol Cell Biochem, 2021, 476(2):743-755. doi: 10.1007/s11010-020-03940-2. doi: 10.1007/s11010-020-03940-2 pmid: 33070276
[24]	Abdullah MI, Abed MN, Khanim F, et al. Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death[J]. Sci Rep, 2019, 9(1):9632. doi: 10.1038/s41598-019-46102-1. doi: 10.1038/s41598-019-46102-1 pmid: 31270377
[25]	Kato S, Liberona MF, Cerda-Infante J, et al. Simvastatin interferes with cancer ′stem-cell′ plasticity reducing metastasis in ovarian cancer[J]. Endocr Relat Cancer, 2018, 25(10):821-836. doi: 10.1530/ERC-18-0132. doi: 10.1530/ERC-18-0132
[26]	Harding BN, Delaney JA, Urban RR, et al. Use of Statin Medications Following Diagnosis in Relation to Survival among Women with Ovarian Cancer[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(7):1127-1133. doi: 10.1158/1055-9965.EPI-18-1194. doi: 10.1158/1055-9965.EPI-18-1194
[27]	Jeong GH, Lee KH, Kim JY, et al. Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis[J]. J Clin Med, 2020, 9(2):326. doi: 10.3390/jcm9020326. doi: 10.3390/jcm9020326
[28]	Feng JL, Dixon-Suen SC, Jordan SJ, et al. Statin use and survival among women with ovarian cancer: an Australian national data-linkage study[J]. Br J Cancer, 2021, 125(5):766-771. doi: 10.1038/s41416-021-01460-4. doi: 10.1038/s41416-021-01460-4
[29]	Hanley GE, Kaur P, Berchuck A, et al. Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada[J]. Gynecol Oncol, 2021, 162(2):461-468. doi: 10.1016/j.ygyno.2021.05.021. doi: 10.1016/j.ygyno.2021.05.021 pmid: 34090707
[30]	Majidi A, Na R, Dixon-Suen S, et al. Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis[J]. Gynecol Oncol, 2020, 157(3):678-685. doi: 10.1016/j.ygyno.2020.03.028. doi: S0090-8258(20)30253-5 pmid: 32317171